Penumbra Inc (NYSE:PEN) CFO Sridhar Kosaraju sold 5,000 shares of the firm’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $142.89, for a total value of $714,450.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Sridhar Kosaraju also recently made the following trade(s):
- On Thursday, May 2nd, Sridhar Kosaraju sold 5,000 shares of Penumbra stock. The shares were sold at an average price of $130.25, for a total value of $651,250.00.
- On Monday, April 1st, Sridhar Kosaraju sold 5,000 shares of Penumbra stock. The shares were sold at an average price of $143.45, for a total value of $717,250.00.
- On Monday, March 11th, Sridhar Kosaraju sold 5,000 shares of Penumbra stock. The shares were sold at an average price of $139.84, for a total value of $699,200.00.
Penumbra stock traded down $0.02 during trading hours on Friday, reaching $160.00. 372,700 shares of the company’s stock were exchanged, compared to its average volume of 402,262. The company has a debt-to-equity ratio of 0.11, a current ratio of 6.10 and a quick ratio of 4.34. The stock’s 50 day moving average price is $150.48. Penumbra Inc has a twelve month low of $110.84 and a twelve month high of $170.00. The firm has a market cap of $5.63 billion, a price-to-earnings ratio of 313.73, a PEG ratio of 8.63 and a beta of 0.60.
PEN has been the subject of a number of research reports. William Blair initiated coverage on Penumbra in a research note on Tuesday, May 21st. They issued an “outperform” rating for the company. HC Wainwright reaffirmed a “buy” rating on shares of Penumbra in a research report on Wednesday, April 17th. ValuEngine lowered Penumbra from a “buy” rating to a “hold” rating in a research report on Thursday, February 28th. Zacks Investment Research lowered Penumbra from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. Finally, Bank of America raised their target price on Penumbra from $150.00 to $180.00 and gave the stock a “buy” rating in a research report on Thursday, June 13th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Penumbra presently has a consensus rating of “Buy” and a consensus price target of $164.17.
Institutional investors and hedge funds have recently modified their holdings of the company. Botty Investors LLC acquired a new stake in shares of Penumbra in the 1st quarter valued at about $29,000. Manchester Capital Management LLC acquired a new position in Penumbra during the 1st quarter valued at about $30,000. PNC Financial Services Group Inc. boosted its stake in Penumbra by 30.8% during the 4th quarter. PNC Financial Services Group Inc. now owns 437 shares of the company’s stock valued at $53,000 after purchasing an additional 103 shares during the last quarter. Capital Investment Advisory Services LLC acquired a new position in Penumbra during the 4th quarter valued at about $56,000. Finally, Gemmer Asset Management LLC boosted its stake in Penumbra by 1,005.1% during the 1st quarter. Gemmer Asset Management LLC now owns 431 shares of the company’s stock valued at $63,000 after purchasing an additional 392 shares during the last quarter. Institutional investors own 86.59% of the company’s stock.
Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands.
Read More: What Are Cryptocurrencies?
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.